Triple marker (alpha-fetoprotein, unconjugated estriol, human chorionic gonadotropin) versus alpha-fetoprotein plus free-beta subunit in second-trimester maternal serum screening for fetal Down syndrome: a prospective comparison study

What Was Tested

The paper reports a study of hCG (human chorionic gonadotropin) in the context of alpha-gal syndrome, published as a clinical trial.

Who Took Part

PubMed indexes the participants as teenagers, adults and middle-aged adults, women only.

How the Study Was Run

Free beta-human chorionic gonadotropin was concurrently assayed in 2349 maternal serum samples.

Trivariate and bivariate algorithms were used to calculate the risk for fetal Down syndrome by the two protocols.

Free beta-human chorionic gonadotropin from 12 cases of fetal Down syndrome previously screened with the triple marker was retrospectively assayed.

What Was Measured

Topics PubMed links to this paper include Biomarkers, Chorionic Gonadotropin, Chorionic Gonadotropin, beta Subunit, Human, Down Syndrome, Estriol, False Positive Reactions and Fetal Diseases.

What This Means in Plain Language

This is a clinical trial of hCG (human chorionic gonadotropin) in people with alpha-gal syndrome.

Results are reported in around 6 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 1995 (American journal of obstetrics and gynecology), a journal based in United States.

More context: the hCG (human chorionic gonadotropin) compound page, Alpha-gal syndrome research.